Intratumoral chemotherapy.
In an effort to improve survival from malignant gliomas, investigators have used intratumoral chemotherapy protocols to deliver high doses of tumoricidal agents directly to the brain. Theoretically, these infusions bypass the blood-brain barrier, minimize systemic drug levels and the side effects of chemotherapy, and achieve prolonged elevations of intracerebral chemotherapeutic agents relative to those obtainable by systemic administration. Almost all major classes of chemotherapeutic agents have been examined as possible intratumoral therapies via delivery approaches ranging from simple intratumoral injections to implantable computer-driven constant infusion pumps and biodegradable polymer matrices. In this review, we summarize the major clinical trials and experimental investigations underlying the development of intratumoral chemotherapy as a treatment for gliomas.
Walter
K A
KA
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Tamargo
R J
RJ
Olivi
A
A
Burger
P C
PC
Brem
H
H
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004343:Drug Implants; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D015918:Infusion Pumps, Implantable; D015552:Injections, Intralesional; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004343:Drug Implants